Introduction
============

*Salmonella sp*. and *Shigella sp* infections are public health threat worldwide, particularly in Sub-Saharan Africa including in Rwanda. This study was done to identify *Salmonella sp*. and *Shigella sp*. currently circulating in Rwanda and determine their drug susceptibility pattern.

Objectives
==========

To determine the prevalence of *Salmonella spp.* and *Shigella spp.* strains circulating in Rwanda and their susceptibilty pattern in Rwanda.

Methods
=======

196 blood and 24 stool specimens from patients were analyzed in Laboratory of Rwanda for culture isolation, identification and drug-sensitivity testing.

Results
=======

91 (92.2 %) of them were identified as *Salmonella enterica* serovar Typhi, 10 were *Shigella sp*. The isolates were subsequently subjected to antibiotic susceptibility tests and the strains of *S*.Typhi isolates were found to be susceptible to cefotaxime (100%), and ciprofloxacin (97.9 %) and resistant to nalidixic acid (89.4%), cotrimoxazole (87.2%). With regard to *Shigella* infections, the antibiotics which showed 100% susceptibility to all species identified were ciprofloxacine, cefotaxime, ceftazidine.

Conclusion
==========

The prevalent *Salmonella* strain circulating in Rwanda is *S*.Typhi and two most useful drugs of choice to treat *Salmonella sp*. and *Shigella sp*. infections in Rwanda are cefotaxime and ciprofloxacin.
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